

Statement on the FDA's Updated Opioid Pain Medication Labeling to Emphasize Risks

The statement below is on behalf of the National Prescription Opiate Litigation Plaintiffs' Executive Committee co-leads Joe Rice of Motley Rice LLC; Jayne Conroy of Simmons Hanly Conroy; and Paul T. Farrell Jr. of Farrell & Fuller Law LLC, on the Food and Drug Administration's updated requirements on opioid medication labels.

“These FDA changes are consistent with what we have been fighting for on behalf of our thousands of clients in the ongoing eight-year national opioid litigation. We believe there is more work to be done, such as required prescriber training, improvements to the FDA's new medication approval process and its post-market reviews of potential problems. We hope the agency will remain steadfast in instituting sustainable changes for the good of the public.”

###